We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sensitive Urine Assay Detects Prostate Cancer

By LabMedica International staff writers
Posted on 29 Aug 2011
An innovative prostate screening test has been developed that may be more sensitive in detecting prostate cancer than traditional screening methods. More...


The test provides an original way to look at prostate cancer diagnosis utilizing a novel biological assay, which differentiates prostate-specific antigen's (PSA) molecular structures arising from cancer versus noncancerous glands.

Scientists at Case Western Reserve University School of Medicine collaborating with other institutions, studied a urine-based test that works differently than most prostate screening methods. They used a novel assay to separate PSA protein structures as being linked to either a “cancer” or “noncancer” pathologic diagnosis based on ultrasound-guided biopsy. Instead of attempting to find a single genetic biomarker, which predicts the presence of cancer, the Prostate-specific Antigen/Solvent Interaction Analysis (PSA/SIA) assay is based on the assumption that there may be myriad different ultrastructural changes in the PSA protein, which define the cancer phenotype.

The PSA/SIA assay determined the relative partitioning of heterogeneous PSA isoform populations in urine between two aqueous phases. The initial study, collected at three clinical sites, followed 222 men, and found that the new screening method had 100% sensitivity with no false negative results and 80.3% specificity showing low false positive results. The accuracy of traditional serum PSA is limited by both relatively high false positive and false negative rates. Current diagnostic strategies that use total PSA to determine the need for biopsy demonstrate false positive rates of approximately 55% to 75%.

The PSA/SIA assay, a product of AnalizaDx (Cleveland, OH, USA) provides ratiometric information independently of PSA concentration. In the preliminary study, analysis of the overall structurally heterogeneous PSA isoform population using the SIA assay showed promising results to be further evaluated in future studies. Arnon Chait, PhD, CEO of AnalizaDx, said, "This new assay is a complete departure from how the scientific community has looked at biomarkers for cancer. Instead of just measuring levels of proteins, we are exploring changes in structure which are associated with cancer.” The study was published online on July 22, 2011, in the journal Urology.

Related Links:
Case Western Reserve University School of Medicine
AnalizaDx




Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.